Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, van der Meer AD, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M. Alb M, et al. Among authors: rubic schneider t. J Immunotoxicol. 2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10. J Immunotoxicol. 2024. PMID: 39655500 Free article. Review.
Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration.
Langlois JB, Brenneisen S, Rodde S, Vangrevelinghe E, Rose G, Lerch P, Sorge M, Ullrich T, Patora-Komisarska K, Quancard J, Larger P, Gianola L, Textor C, Chenal G, Rubic-Schneider T, Simkova K, Masmanidou O, Scheufler C, Lammens A, Bouzan A, Demirci S, Flotte L, Rivet H, Hartmann L, Guezel D, Flueckiger M, Schilb A, Schuepbach E, Kettle R, Jacobi C, Pearson D, Richards PJ, Minetti GC. Langlois JB, et al. Among authors: rubic schneider t. J Med Chem. 2024 Dec 12;67(23):21163-21185. doi: 10.1021/acs.jmedchem.4c01938. Epub 2024 Nov 22. J Med Chem. 2024. PMID: 39576936
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.
Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, Koepke S, Cochin de Billy B, Ledieu D, Andre C, Hawtin S, Fischer B, Moretti F, Hug C, Bepperling A, Brannetti B, Mendez-Garcia C, Littlewood-Evans A, Clemens A, Grosskreutz CL, Mehan P, Schmouder RL, Sasseville V, Brees D, Karle AC. Kearns JD, et al. Among authors: rubic schneider t. Sci Transl Med. 2023 Feb;15(681):eabq5068. doi: 10.1126/scitranslmed.abq5068. Epub 2023 Feb 1. Sci Transl Med. 2023. PMID: 36724241
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.
Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, Rubic-Schneider T, Pruimboom-Brees I, Leber XC, Scharenberg M, Maciejewski B, Turner O, Saravanan C, Huet F, Littlewood-Evans A, Clemens A, Grosskreutz CL, Kearns JD, Mehan P, Schmouder RL, Sasseville V, Brees D. Karle AC, et al. Among authors: rubic schneider t. Sci Transl Med. 2023 Feb;15(681):eabq5241. doi: 10.1126/scitranslmed.abq5241. Epub 2023 Feb 1. Sci Transl Med. 2023. PMID: 36724238
Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, Rieble L, Keller CW, Prummer M, Hoffmann L, Lam JKP, Chiang AKS, Raulf F, Azzi T, Berger C, Rubic-Schneider T, Traggiai E, Lünemann JD, Kammüller M, Münz C. Caduff N, et al. Among authors: rubic schneider t. PLoS Pathog. 2020 Dec 21;16(12):e1009167. doi: 10.1371/journal.ppat.1009167. eCollection 2020 Dec. PLoS Pathog. 2020. PMID: 33347498 Free PMC article.
Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
Martin K, Junker U, Tritto E, Sutter E, Rubic-Schneider T, Morgan H, Niwa S, Li J, Schlapbach A, Walker D, Bigaud M, Beerli C, Littlewood-Evans A, Rudolph B, Laisney M, Ledieu D, Beltz K, Quancard J, Bornancin F, Zamurovic Ribrioux N, Calzascia T. Martin K, et al. Among authors: rubic schneider t. Front Immunol. 2020 Apr 30;11:745. doi: 10.3389/fimmu.2020.00745. eCollection 2020. Front Immunol. 2020. PMID: 32425939 Free PMC article.
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, Rieble L, Keller CW, Prummer M, Hoffmann L, Lam JKP, Chiang AKS, Raulf F, Azzi T, Berger C, Rubic-Schneider T, Traggiai E, Lünemann JD, Kammüller M, Münz C. Caduff N, et al. Among authors: rubic schneider t. PLoS Pathog. 2020 Apr 6;16(4):e1008477. doi: 10.1371/journal.ppat.1008477. eCollection 2020 Apr. PLoS Pathog. 2020. PMID: 32251475 Free PMC article.
16 results